Connect with us

Technology

ECRI Spins Out Healthcare Spend Management and Recall Management Solutions

Published

on

Staritas established with growth investment from Accel-KKR to transform healthcare supply chain through data-driven intelligence

WILLOW GROVE, Pa., April 21, 2026 /PRNewswire/ — ECRI, a global healthcare quality and safety nonprofit organization, today announced that it has spun out its Spend Management and Recall Management solutions as an independent company, Staritas. Powered by investments from Accel-KKR, a global technology-focused investment firm, Staritas will continue to build on its pioneering leadership in healthcare supply chain intelligence.

“For five decades, ECRI’s award-winning Spend Management solutions have helped healthcare supply chain leaders navigate supply disruptions with resiliency, save millions of dollars, and benchmark purchasing decisions using the industry’s most comprehensive, independent datasets,” said Marcus Schabacker, CEO, MD, president of ECRI. “Now, by spinning out Staritas, powered by Accel-KKR to supercharge the power behind the data, improve the user experience, and accelerate innovation, healthcare supply chain leaders can realize even greater value from the platform.”

The healthcare supply chain of the future will no longer be driven by reactive, event-driven decisions, but proactive, continuous strategies, powered by AI and real-time intelligence. As an independent company backed by Accel-KKR, Staritas will expand on the development and delivery of AI-powered solutions and insights that empower leaders to manage the growing complexity of supply chains with greater intelligence.

“We are excited to partner with ECRI and support the launch of Staritas, a new company with a 50- year track record of pioneering work in spend and recall management,” said Park Durrett, Managing Director at Accel-KKR. “Staritas’s unmatched independent datasets and domain expertise create a strong foundation for growth and customer impact. We’re proud to build on Staritas’s legacy and remain committed to the transparency, independence, and objectivity that define its work. We look forward to partnering with the talented Staritas team to keep building on a market-leading platform that delivers greater value to healthcare organizations and stakeholders worldwide.”

Staritas: Making Every Choice Clear

In today’s healthcare environment, leaders face rising costs, margin pressure, supply chain disruptions, and increasing complexity, often making decisions with fragmented information, such as supplier pricing without benchmarks, or investments without a clear view of total cost.

Staritas solves this problem by combining the largest independent source of healthcare supply and capital datasets with deep expertise and advanced analytics to help organizations in over 70 countries understand market trends and better manage their supply chains. Trusted by nearly 90% of the top U.S. hospitals and health systems, Staritas helps customers identify up to $13 billion annually in opportunity savings. With an independent, unbiased view, supply chain leaders can see all their options, seize opportunities through actionable insights, and make confident decisions.

“Staritas is committed to providing data-driven insights and services that help healthcare organizations optimize operations, save money and strengthen decision making,” said Emmet O’Gara, CEO of Staritas. “The data, solutions and people that now make up Staritas are among the best in the field of spend and recall management. We plan to continuously raise the bar in serving healthcare supply chain leaders with next-generation platform and technology advancements that help to protect margins, deliver quality care and boost resiliency.”

Customers will maintain continuity in day-to-day operations, with additional investments planned to enhance platform capabilities and deepen the value delivered across solutions. Users of Staritas products were notified with assurances of a smooth transition and continuity in the personnel and support systems available.

ECRI: Making Healthcare Safer, Stronger, More Resilient

“This move is not a departure, it is a commitment to deepening ECRI’s focus on patient safety, clinical evidence, and system-level change across healthcare,” added ECRI CEO Dr. Schabacker. “ECRI’s services and solutions are now focused exclusively on creating resilient and safe healthcare systems and assessing technologies used in those systems – backed by new investment and commitment to effect transformative change. With this strategic shift, ECRI is investing, at an unprecedented level, in the expert teams, proprietary data assets, and advanced capabilities that allow healthcare organizations to build safety into their culture, their operations, and their systems. Not as a one-time initiative, but as a permanent, self-reinforcing foundation.”

Despite decades of effort nationwide, patient safety in the U.S. is still marked by high rates of preventable harm.

“One in four patient admissions involve an adverse event, and nearly a quarter of those are preventable. That’s tragic and unacceptable,” said Dheerendra Kommala, MD, ECRI Chief Medical Officer. “Through this strategic move, ECRI is now singularly focused on improving patient safety. We plan to expand solutions that can transform healthcare organizations, building on our legacy of advancing evidence-based medicine.”

About ECRI

ECRI is an independent, nonprofit organization improving the safety, quality, and cost-effectiveness of healthcare. With a focus on patient safety, system design and technology evaluation, ECRI is respected and trusted by healthcare leaders and agencies worldwide. For nearly 60 years, ECRI has built its reputation on integrity and disciplined rigor, with an unwavering commitment to independence and evidence-based care. ECRI is the only organization worldwide to conduct independent medical device evaluations, with labs located in North America and Asia Pacific. ECRI is designated an Evidence-based Practice Center by the U.S. Agency for Healthcare Research and Quality and a federally certified Patient Safety Organization by the U.S. Department of Health and Human Services. ECRI acquired The Institute for Safe Medication Practices (ISMP) in 2020 to address one of the most prolific causes of preventable harm in healthcare, medication errors; then acquired The Just Culture Company in 2024 to transform healthcare workplace cultures – thus creating one of the largest healthcare quality and safety entities in the world. Visit ECRI.org to learn more.

About Staritas

Staritas helps healthcare supply chain leaders around the world make more informed decisions so they can understand market trends and better manage all aspects of their supply chain. With Staritas, they can see all the options with the largest independent source of supply and capital data, seize the opportunities with access to deep industry expertise, and achieve their organizational goals. That’s why nearly 90% of the top U.S. hospitals and health systems trust our five decades of expertise for their most important supply chain and recall management decisions. And it’s how our clients find up to $13B dollars in opportunity savings every year. Staritas. Make every choice clear. Learn more at Staritas.com.

About AKKR

Accel-KKR is a technology-focused investment firm with over $23 billion in cumulative capital commitments. The firm focuses on software and tech-enabled businesses, well-positioned for topline and bottom-line growth. At the core of Accel-KKR’s investment strategy is a commitment to developing strong partnerships with the management teams of its portfolio companies and a focus on building value alongside management by leveraging the significant resources available through the Accel-KKR network. Accel-KKR focuses on middle-market companies and provides a broad range of capital solutions, including buyout capital, minority-growth investments, and credit alternatives. Accel-KKR also invests across various transaction types, including private company recapitalizations, divisional carve-outs, and going-private transactions. Accel-KKR’s headquarters is in Menlo Park, with offices in London, Atlanta and Chicago. Visit accel-kkr.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ecri-spins-out-healthcare-spend-management-and-recall-management-solutions-302747800.html

SOURCE ECRI

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Hexagon Interim Report 1 January – 31 March 2026

Published

on

By

STOCKHOLM, April 23, 2026 /PRNewswire/ —

First quarter 2026

Continuing operations

Operating net sales of 963.8 (961.5) resulting in organic growth of 8%Net sales including acquired deferred revenue amounted to 963.6 MEUR (961.5)Adjusted gross earnings of 606.3 (619.1) resulting in a 62.9% (64.4) gross marginAdjusted operating earnings (EBIT1) of 251.3 MEUR (248.7) resulting in a 26.1% (25.9) EBIT1 marginAdjusted earnings per share of 6.7 Euro cent (6.5)Earnings per share of 58.4 Euro cent (5.0)Cash conversion of 77% (60)Recurring revenue of 289.9 MEUR (308.0), 6% organic growthOctave reported operating net sales of 327.2 MEUR (361.3) and adjusted operating margin of 25.2% (26.6)Adjusted earnings per share including discontinued operations of 9.1 (9.4)Earnings per share including discontinued operations of 59.9 Euro cent (7.0)

For further information, please contact:
Tom Hull, Head of Investor Relations, +44 (0) 7442 678 437, ir@hexagon.com
Anton Heikenström, Investor Relations Manager, +46 8 601 26 26, ir@hexagon.com

This is information that Hexagon AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on 23 April 2026.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hexagon/r/hexagon-interim-report-1-january—31-march-2026,c4338783

The following files are available for download:

 

View original content:https://www.prnewswire.com/news-releases/hexagon-interim-report-1-january—31-march-2026-302751432.html

SOURCE Hexagon

Continue Reading

Technology

Dragonpass Empowers Financial Institutions with End-to-End Loyalty Solutions at Money20/20 Asia

Published

on

By

BANGKOK, April 23, 2026 /PRNewswire/ — Dragonpass, a leading global travel and lifestyle platform, participated in Money20/20 Asia, showcasing its customer loyalty solutions for banks, payment providers, credit card issuers, and fintech companies across APAC and globally.

As one of the most influential fintech events worldwide, Money20/20 Asia gathers decision-makers across the financial ecosystem. At the event, Dragonpass demonstrated how financial institutions can enhance customer engagement and build long-term loyalty through integrated travel and lifestyle experiences.

Established in 2005, Dragonpass has evolved from a lounge provider into a loyalty solutions partner, serving more than 800 global clients and over 40 million members worldwide.

At the core of Dragonpass is a business structure that combines global supply aggregation, a technology-enabled engagement platform, and consumer-facing lifestyle services — providing a one-stop solution across the customer lifecycle.

Leveraging data-driven insights, Dragonpass enables partners to design and optimise loyalty programs, incorporating customer segmentation and tiered incentive structures, alongside curated campaigns and entitlement configuration — driving more effective customer activation, engagement, and retention.

Its offering includes a broad portfolio of travel and lifestyle benefits such as airport lounge access, fast-track, dining, airport transfers, and lifestyle experiences. These are supported by flexible delivery models, including API integration, white-label solutions, and ready-to-deploy digital platforms, enabling seamless integration into clients’ customer journeys.

As customer expectations evolve, the industry is shifting from standardized benefits to more personalized, experience-led loyalty models. Insights from Dragonpass’s Loyalty Index show that customers increasingly value trust, rewards, simplicity, recognition, and exclusivity, with preferences varying across markets.

“Financial institutions today are looking for more effective ways to engage customers beyond traditional rewards,” said Jane Zhu, Co-founder and CEO of Dragonpass. “User engagement is at the core of loyalty, and technology — especially AI — plays a key role in enabling deeper and more relevant customer connections.”

Dragonpass works with leading global brands including Mastercard, Visa, HSBC, and Revolut, supporting them deliver differentiated value propositions and enhance customer engagement through scalable, customizable solutions.

Through its participation at Money20/20 Asia, Dragonpass aims to strengthen its presence in the APAC market and build strategic partnerships with organizations seeking to elevate their customer engagement strategies.

About Dragonpass

Dragonpass is a global travel and lifestyle platform providing premium airport and travel experiences across 140+ countries. By integrating global supply and technology, Dragonpass enables partners to deliver seamless, personalized experiences and drive customer loyalty.

Media Contact

Dragonpass PR
Email: brandmarketing@dragonpass.com
Website: www.dragonpass.com

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/dragonpass-empowers-financial-institutions-with-end-to-end-loyalty-solutions-at-money2020-asia-302751442.html

SOURCE Dragonpass

Continue Reading

Technology

SBI Life Insurance registers New Business Premium of ₹42,551 crores for the year ended on 31st March, 2026

Published

on

By

MUMBAI, India, April 23, 2026 /PRNewswire/ — SBI Life Insurance, one of the leading life insurers in the country registered a New Business Premium of ₹42,551 crores for the year ended on 31st March, 2026 vis-a-vis ₹35,577 crores for the year ended 31st March, 2025. Single premium has increased by 28% over the year ended on 31st March, 2025.

Establishing a clear focus on protection, SBI Life’s protection new business premium stood at ₹4,622 crores for the year ended 31st March, 2026, marking a growth of 13%. Protection Individual new business premium registered a growth of 23% and stood at ₹973 crores for the year ended 31st March, 2026. Individual New Business Premium stands at ₹29,783 crores with 13% growth over the year ended on 31st March, 2025.

SBI Life’s profit after tax stands at ₹2,470 crores for the year ended 31st March, 2026 with a growth of 2% over the year ended on 31st March, 2025.

The company’s solvency ratio continues to remain robust at 1.90 as on 31st March, 2026 as against the regulatory requirement of 1.50.

SBI Life’s AUM also continued to grow at 9% to ₹4,87,163 crores as on 31st March, 2026 from ₹4,48,039 crores as on 31st March, 2025, with the debt-equity mix of 62:38. 94% of the debt investments are in AAA and Sovereign instruments.

The company has a diversified distribution network of 3,58,506 trained insurance professionals and wide presence with 1,230 offices across the country, comprising of strong bancassurance channel, agency channel and others comprising of corporate agents, brokers, Point of Sale Persons (POS), insurance marketing firms, web aggregators and direct business.

Performance for the year ended March 31, 2026

Private Market leadership in Individual New Business Premium and Individual Rated Premium with market share of 25.5% & 22.9% respectively.Annualized Premium Equivalent (APE) stands at ₹ 24,266 crores with growth of 13%Individual New Business Sum Assured stands at ₹ 4,46,337 crores with 61% growthImprovement in 13M & 49M persistency by 53 bps & 107 bps respectivelyValue of New Business (VoNB) stands at ₹ 6,667 crores with growth of 12%VoNB Margin stands at 27.5%Indian Embedded value (IEV) stands at ₹ 80,791 crores with 15% growthProfit After Tax (PAT) stands at ₹ 2,470 crores with 2% growthOperating Return on Embedded Value stands at 19.7% Assets under Management stands at ₹ 4,87,163 crores with 9% growthRobust Solvency ratio of 1.90

Logo: https://mma.prnewswire.com/media/2672544/SBI_Life_25_Years_Logo.jpg

 

View original content:https://www.prnewswire.com/in/news-releases/sbi-life-insurance-registers-new-business-premium-of-42-551-crores-for-the-year-ended-on-31st-march-2026–302751447.html

Continue Reading

Trending